HPV and Chlamydia trachomatis co-detection in young asymptomatic women from high incidence area for cervical cancer

Journal of Medical Virology

Volumn 86, Issue 11, 2014, Pages 1920-1925

  Bellaminutti, Serena ^a   Seraceni, Silva ^b   de Seta, Francesco ^a,b   Gheit, Tarik ^c   Tommasino, Massimo ^c   Comar, Manola ^a,b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cancer co factors; Cervical lesions; Chlamydia trachomatis; Chlamydia trachomatis screening; Human papillomavirus

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BACTERIUM IDENTIFICATION; CANCER SCREENING; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MIXED INFECTION; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS IDENTIFICATION; WART VIRUS; ADOLESCENT; AGE; CHLAMYDIA INFECTIONS; CLASSIFICATION; COINFECTION; COMPLICATION; GENETICS; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVIX; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; CERVIX UTERI; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COINFECTION; FEMALE; GENOTYPE; HUMANS; INCIDENCE; ITALY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; YOUNG ADULT;

EID: 84944224992     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24041     Document Type: Article

References (29)

1. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26: K1-16.
2. Bosch FX, Tsu V, Vosters A, Van Damme P, Kane MA. 2012. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine 30:F1-11.
3. Braaten KP, Laufer MR. 2008. Human Papillomavirus (HPV), HPVRelated Disease, and the HPV Vaccine. Rev Obstet Gynecol 1:2-10.12.
4. Choroszy-Król IC, Frej-Madrzak M, Jama-Kmiecik A, Bober T, Jolanta Sarowska J. 2012. Characteristics of the Chlamydia trachomatis species-immunopathology and infections. Adv Clin Exp Med 21:799-808.
5. Comar M, Iannacone MR, Casalicchio G, McKay-Chopin S, Tommasino M, Gheit T. 2012. Comparison of hybrid capture II, linear array, and a bead-based multiplex genotyping assay for detection of human papillomavirus in women with negative pap test results and atypical squamous cells of undetermined significance. J Clin Microbiol 50:4041-4046.
6. Cooksey CM, Berggren EK, Lee J. 2010. Chlamydia trachomatis Infection in minority adolescent women: a public health challenge. Obstet Gynecol Surv 11:729-735.
7. Fernández-Benítez C, Mejuto-López P, Otero-Guerra L, Margolles-Martins MJ, Suárez-Leiva P, Vazquez F. Chlamydial Primary Care Group. 2013. Prevalence of genital Chlamydia trachomatis infection among young men and women in Spain. BMC Infect Dis 13:388.
8. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. 2012. Global burden of human papillomavirus and related diseases. Vaccine 30:F12-F23.
9. Gheit T, Landi S, Gemignani F, Snijders PJ, Vaccarella S, Franceschi S, Canzian F, Tommasino M. 2006. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol 44:2025-2031.
10. Gottlieb SL, Xu F, Brunham RC. 2013. Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials. Sex Transm Dis 2:97-102.
11. Grieshaber SS, Grieshaber NA, Miller N, Hackstadt T. 2006. Chlamydia trachomatis causes centrosomal defects resulting in chromosomal segregation abnormalities. Traffic 7:940-949.
12. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. 2010. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 201:S134-155.
13. Honey E, Augood C, Templeton A, Russell I, Paavonen J, Mårdh PA, Stary A, Stray-Pedersen B. 2002. Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies. Sex Transm Infect 78:406-412.
14. Idahl A, Lundin E, Elgh F, Jurstrand M, Møller JK, Marklund I, Lindgren P, Ottander U. 2010. Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. Am J Obstet Gynecol 202:71.
15. Knowlton AE, Brown HM, Richards TS, Andreolas LA, Patel RK, Grieshaber SS. 2011. Chlamydia trachomatis infection causes mitotic spindle pole defects independently from its effects on centrosome amplification. Traffic 12:854-866.
16. Luostarinen T, Namujju PB, Merikukka M, Dillner J, Hakulinen T, Koskela P, Paavonen J, Surcel HM, Lehtinen M. 2013. Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study. Int J Cancer 133:1756-1759.
17. Marcone V, Recine N, Gallinelli C, Nicosia R, Lichtner M, Degener AM, Chiarini F, Calzolari E, Vullo V. 2012. Epidemiology of Chlamydia trachomatis endocervical infection in a previously unscreened population in Rome, Italy, 2000 to 2009. Euro Surveill 17:20203.
18. Muñoz N, Kato I, Bosch FX, Eluf-Neto J, De Sanjosé S, Ascunce N, Gili M, Izarzugaza I, Viladiu P, Tormo MJ, Moreo P, Gonzalez LC, Tafur L, Walboomers JM, Shah KV. 1996. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 23: 504-5510.
19. Nelson HD, Helfand M. 2001. Screening for Chlamydial Infection. Am J Prev Med 20:95-107.
20. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, de Sanjosé S, Muñoz N. IARC Multi-centre Cervical Cancer Study Group. 2003. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 9:805-814.
21. SamoffE, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER. 2005. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 162:668-675.
22. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. 2010. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 48: 143-149.
23. Shew ML, Ermel AC, Weaver BA, Tong Y, Tu W, Kester LM. 2013. Association of Chlamydia trachomatis Infection With Redetection of Human Papillomavirus After Apparent Clearance. J Infect Dis 208:1416-1421.
24. Silins I, Ryd W, Strand A, Wadell G, Törnberg S, Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson K, Dillner J, Rylander E. 2005. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 116:110-115.
25. Simonetti AC, Melo JH, De Souza PR, Bruneska D, de Lima Filho JL. 2009. Immunological's host profile for HPV and Chlamydia Trachomatis, a cervical cancer cofactor. Microbes Infect 11:435-442.
26. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N. Forum Group Members. Bethesda 2001 Workshop. 2002. The 2001 Bethesda System: terminology for reporting results of cervical cytology JAMA 287:2114-2119.
27. Verteramo R, Pierangeli A, Mancini E, Calzolari E, Bucci M, Osborn J. 2009. Human Papillomaviruses and genital co-infections in gynaecological outpatients. BMC Inf Dis 9:16.
28. Wilson JS, Honey E, Templeton A, Paavonen J, Mårdh PA, Stray-Pedersen B. EU Biomed Concerted Action Group. 2002. A systematic review of the prevalence of Chlamydia trachomatis among European women. Hum Reprod Update 8:385-394.
29. Workowski KA, Berman S. 2011. Centers for Disease Control and Prevention (CDC) Sexually transmitted diseases treatment guidelines. Clin Infect Dis 53:S59-63.